FDA INVESTIGATING DEATH DUE TO NEUTRALIZING ANTIBODIES TO ADAMTS13 FOLLOWING ADZYNMA TREATMENT OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.